PowerPoint Presentation

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Phase II trial, study end 2020 Intervention - Single Group Assignment

INCLUSION CRITERIA: cSCC that is not curable by surgery or radiation; both locally advanced and metastatic squamous cell carcinoma will be included.

PRIMARY OBJECTIVE: -To establish the response rate of pembrolizumab in metastatic cutaneous squamous cell carcinoma. SECONDARY OBJECTIVES: -To determine the 6-month progression-free survival and 1 year overall survival of mcSCC treated with pembrolizumab OUTLINE: Pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 8-12 weeks.